Here's what the broker is recommending to clients this week:

Adveritas Ltd (ASX: AV1)

Adveritas is a technology company that develops software solutions for enterprise customers which help maximise the return on digital ad spend.

Bell Potter is expecting the ASX share to deliver another strong update this month. In fact, it is expecting its annual recurring revenue (ARR) to double on the prior corresponding period. It said:

We expect another solid quarter when Adveritas releases its Quarterly Activities Report & Appendix 4C towards the end of this month though we do see some potential headwinds from both contract delays – due to macro uncertainty – and/or unfavourable currency movements. We forecast ARR of c.$16m at 31 March which is up 11% q-o-q and >100% y-o-y.

Bell Potter has retained its buy rating and 20 cents price target on its shares. This is more than double its current share price. Commenting on its buy recommendation, it said:

There are no changes in the key assumptions we apply in the two valuations used to determine our target price (5x multiple in the EV/Revenue and 10.1% WACC in the DCF). With no change in our forecasts there is, therefore, no change in our target price of $0.20 and we retain our BUY recommendation.

We continue to see multiple growth levers for the company including the cross-sell of Meta and Affiliate products to existing customers, the expansion into new verticals (such as eCommerce) and the recent launch of the self-serve platform (which better addresses the SME market). The negative perhaps is the modest cash balance of c.$6m though the company is near or around cash flow breakeven so in our view is not necessarily cum an equity raise.

EMvision Medical Devices Ltd (ASX: EMV)

Another ASX share that could have major upside potential is EMvision.

It is a medical device company focused on the development of a portable, cost-effective, non-ionising and safe brain scanner which is capable of rapidly determining the presence of suspected stroke and stroke type to provide game-changing insights for clinicians.

Bell Potter has been pleased with its operational progress and highlights positive developments with its ongoing trial. It explains:

Eight leading hospitals are now actively recruiting, even on an after-hours basis. To date there have been no device-related adverse events. A full trial progress update is expected later this quarter. In a positive sign, one of the trial participants, Memorial Hermann recently presented EMV's technology at the NABI-Con. Addressing the unique and compelling way EMV's technology utilises AI for PoC stroke diagnosis.

Bell Potter has retained its speculative buy rating and $3.15 price target on its shares. This is approximately double its current share price. The broker commented:

CY26 is a pivotal year for EMV with an expected successful completion of the current validation trial, leading to potential FDA De Novo clearance by CY27. This will be a critical value inflection point for EMV and is expected to be supported by the various First Responder feasibility studies, with updates during CY26.

The post 2 ASX shares that could rise 100% according to Bell Potter appeared first on The Motley Fool Australia.

Many small-cap companies are depending on clinical trial success, public or private funding, and more to generate consistent profits. 

Because of these risks, share price volatility is common amongst this asset class. 

However, the team at Bell Potter is optimistic about two ASX small caps following important results. 

If you are considering adding a speculative small-cap stock to your portfolio, these two could be worth watching. 

Biome Australia Ltd (ASX: BIO)

Biome Australia (BIO) develops and commercialises clinically backed innovative live biotherapeutics (probiotics), marketing 18 products under the 'Activated Probiotics' Brand. 

The company made headlines earlier this month after it struck a distribution deal for its probiotic products in Canada.

This sent its share price 8% higher on February 2nd. 

Since then, its share price has retreated; however, yesterday, it jumped 6% on first-half FY26 results.

The company reported net profit of $1.18m, up 172% from the prior period, record H1 EBITDA of $1.47m, and record half-year sales revenue of $12.40m, up ~40%. 

Following this announcement, Bell Potter provided updated guidance on the ASX small-cap stock. 

The broker pointed out that the company maintained sales momentum in Australian Pharmacy as well as introduced new retail channels with Mecca (beauty vertical) and Go Vita (health food). 

The broker maintained its buy recommendation and $1 price target. 

From yesterday's closing price of $0.43, this indicates an upside of approximately 132.6%. 

We look forward to the FY26 result, in which we expect to see further improvement in 2H26 sales and margins and more colour on geographic segmentation. Given 1 yr fwd multiples are now c.13x, but the FCF yield is >6% and ROE is >40%, BIO screens positively for long-term fundamental investors.

EMvision Medical Devices Ltd (ASX: EMV)

EMvision Medical Devices is an Australian medical device company. The company is focused on research and development and the commercialisation of neurodiagnostic technology for stroke diagnosis and monitoring. 

Yesterday, the company released its half-year report. Following this announcement, Bell Potter released an updated outlook on the ASX small-cap stock. 

Bell Potter reinforced that CY26 is a pivotal year for the company, with an expected successful completion of the current validation trial, leading to potential FDA De Novo clearance in 4Q CY26/1Q CY27. 

This will be a critical value inflection point for EMV and is expected to be supported by the various First Responder feasibility studies, with updates during CY26.

Bell Potter maintained its speculative buy recommendation on the company, along with a price target of $3.150. 

From yesterday's closing price of $1.775, this indicates an upside of 77.5%. 

The post Two small caps that could double this year appeared first on The Motley Fool Australia.

That's because the speculative ASX stock in this article could rise approximately 80% over the next 12 months according to analysts at Bell Potter.

Here's what it is recommending to clients with a high tolerance for risk.

Which speculative ASX stock?

The stock that is being recommended is EMvision Medical Devices Ltd (ASX: EMV).

It is a medical device company that is aiming to change the stroke care model.

The speculative ASX stock's lead product in development is a portable, cost-effective, non-ionising and safe brain scanner called Emu. It will be capable of rapidly determining the presence of suspected stroke and stroke type to provide game-changing insights for clinicians.

Its second product and likely main revenue generator according to Bell Potter is First Responder. It is a pre-hospital based device the size of a motorcycle helmet that can be used by standard road or air ambulances where fast access to CT/MRI scanning is limited.

Bell Potter notes that the company is progressing through its preparatory phase. It said:

EMV has moved through its preparatory phase and fully activated recruiting for the trial, following completion of onboarding, training verification and site activation processes. A second site at Mt Sinai has been activated and a second site at Memorial Hermann will soon activate to accelerate recruitment.

The network of KOL sites across the trial group should prove valuable in building commercial foundations for the emu product. The Continuous Innovation Study is designed to support algorithm and feature development, while the Regional Benefits Study (RBS) is moving toward an ethics submission with planned activation in 2H CY26. The RBS is designed to support broader adoption of the emu.

The broker also highlights that the speculative ASX stock is running studies for First Responder, with preliminary findings due next month. It adds:

EMV is continuing to move through the Mobile Stroke Unit Study, the Aeromedical Retrieval Study and the Standard Road Ambulance Clinical Study. These studies examine workflow, integration, and usability in a variety of settings, which is necessary for building the 510(k)-application process and commercial prospects. Next month, EMV will be presenting preliminary findings of the Aeromedical study at the International Stroke Conference, giving the First Responder critical exposure to over 6,000 clinicians, researchers, and stroke professionals.

Big potential returns

According to the note, Bell Potter has retained its speculative buy rating and $3.15 price target on the ASX stock.

Based on its current share price of $1.76, this implies potential upside of approximately 80% for investors over the next 12 months.

Bell Potter's bullish view is based on its belief that 2026 will be a pivotal year for the company. It said:

CY26 is a pivotal year for EMV with an expected successful completion of the current validation trial, leading to potential FDA De Novo clearance in 4Q CY26 / 1Q CY27, as well as the completion of the various First Responder feasibility studies. Both these developments should present valuation inflection points for EMV.

The post Why this speculative ASX stock could rise 80% appeared first on The Motley Fool Australia.

That's because analysts at Bell Potter are tipping its shares to rise materially over the next 12 months.

Which small cap ASX share?

The small cap we are going to look at today is EMvision Medical Devices Ltd (ASX: EMV).

It is an Australian medical device company developing a novel approach to looking inside the human body.

It notes that its product pipeline includes portable, non-invasive, affordable, and safe neurodiagnostic devices.

The small cap ASX share states that its vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

What is the broker saying?

Bell Potter highlights that the company has just raised funds. This will allow it to pursue its clinical, regulatory, and commercial activities. It was pleased that the capital raising wasn't as dilutionary as expected. The broker explains:

EMV has raised c.$12m at $1.94 / sh, representing a c.16.4% discount to the last close prior to the raising and a c.6.6% discount to the 15-day VWAP. The raising includes a $1m SPP with capacity for oversubscriptions to $2m, as well as out of the money options to be listed on a 3 for 4 basis at $3.40 / sh with a two-year expiry. The funds raised enable EMV to continue to pursue its clinical, regulatory and commercial activities, while maintaining funding runway. We had assumed a raising of $20m in FY26 at $1.50/sh, so this raising is less dilutionary than expected. If exercised, the options would raise a further c.$18.9m. Pro-forma net cash should equate to c.$21.8m.

Its analysts note that the small cap ASX share is now well-placed to undertake its studies with the hopes of filling an unmet need. It adds:

EMV has announced the commencement of a new Pre-Hospital Mobile Stroke Unit Study to evaluate EMV's First Responder (FR) Brain Scanner in the Melbourne Mobile Stroke Unit (MSU) — one of only ~45 MSUs globally, and one of only two in Australia. The Two-Stage study on 10 suspected stroke patients anticipates reporting in 4QCY25 and includes: Stage 1 – Evaluating the usability and workflow integration of the EMV FR scanner within the MSU environment in the hyperacute stroke phase.

Stage 2 – Utilise the production equivalent FR device, to collect EMV scan data matched with ground-truth radiological imaging (Head CT) to support the advancement and evaluation of EMV's AI-enhanced stroke detection algorithms. Due to size, cost, staffing requirements and complexity of MSUs, a more scalable solution is required to provide broad access to pre-hospital models of stroke care, and EMVs FR seeks to fill this unmet need.

Big potential returns

According to the note, Bell Potter has reaffirmed its speculative buy rating on the company's shares with an improved price target of $3.15 (from $2.95).

Based on its current share price of $1.94, this implies potential upside of 62% for investors over the next 12 months.

The post Why this small cap ASX share could rise 60%+ appeared first on The Motley Fool Australia.

The company is focused on the research and development, and commercialisation of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs.

Its focus is portable, cost-effective, and non-invasive brain scanners. This includes a bedside device (emu) and an ultra-lightweight pre-hospital device (First Responder).

Its share price fell from $2.36 to $2.05 yesterday, representing an 11.64% drop. 

Prior to Wednesday's crash, the ASX health care stock was up 30% over the last 6 months. 

Why did the share price crash?

It seems investors reacted negatively to the announcement of a capital raise.

The company received firm commitments to raise A$12 million via placement at A$1.94/share. 

This means the company will issue new shares to raise A$12 million in total.

The new shares are to be issued at a significant discount (16.4%) from September 12 closing price. 

Is a capital raise bad news?

There are a few factors to consider before jumping ship. 

A capital raise can be positive because it provides a company with much-needed funds to grow, invest in new projects, or reach key milestones – without taking on debt. 

However, it can also be bad for existing shareholders. When it involves issuing new shares, this causes dilution. This often comes at a discount, which can pressure the stock price.

Why is EMVision raising capital?

According to the company announcement, the funds are to be deployed over FY26 and FY27 to advance EMVision through major milestones, including: 

• Supporting clinical program, FDA submission and initial commercialisation activities for the emuTM device
• Advancing the First Responder program through clinical trials, production readiness and regulatory preparation

In simple terms, this capital raising will help provide EMVision with the necessary funds to complete the pivotal clinical trial for its emu brain scanner. It will also support the FDA submission process over FY26 and FY27. 

Having sufficient cash allows the company to invest in regulatory approvals, manufacturing scale-up, and commercialisation efforts. These are key steps to bring the device to market and generate future revenue.

What does this mean for investors?

It is difficult to predict how the market will react to a capital raise. Although the funds will support commercialisation and an FDA submission, these are long-term milestones. 

Some investors may prefer to reallocate funds rather than wait through a potentially volatile development timeline.

Additionally, some investors may have locked in profits before the new shares hit the market, and already sold, which may have contributed to the 12% drop yesterday. 

On the flip side, long term investors may be willing to hold through some short term volatility, seeing the capital raising as a vital injection. 

The capital raised funds may be seen as critical for the development and FDA approval of the emu brain scanner, potentially unlocking significant future revenue if the device succeeds commercially. 

Successfully bringing an innovative medical device to market can boost the company's growth, increase its valuation, and reward patient investors as the business moves from development into sales and expansion.

The post Why did this ASX health care stock just plummet 12%? appeared first on The Motley Fool Australia.

At the time of writing, the S&P/ASX 200 Health Care Index (ASX:XHJ) is down 1.5% over the last year.

Meanwhile, the S&P/ASX 200 Index (ASX: XJO) has risen more than 12%. 

When a sector has a down period, it can be an opportunity for investors to buy-low on companies that could bounce back in the long term. 

One such company that has gained the attention of experts is EMvision Medical Devices Ltd (ASX: EMV). 

What is EMvision?

EMvision Medical Devices is an Australian healthcare company. 

The company is focused on the research and development and commercialisation of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. 

Its focus is portable, cost effective and non-invasive brain scanners, including a bedside device (emu) and an ultra-light weight first responder pre-hospital device.

Over the last 12 months, its share price has fallen more than 17%. 

However, broker Bell Potter has an optimistic view that this ASX healthcare stock could be a buy-low option. 

What did the broker have to say

In a report issued at the end of July, Bell Potter said EMvision Medical Devices is developing a novel approach to Stroke diagnosis / classification and has the potential to bring about a shift in speed of diagnosis and time to treatment.

The pre-validation trial results had encouraging sensitivity / specificity results for both haemorrhagic and ischemic stroke types, leading to the current validation trial for emu across six US / Australian sites, with a target FDA approval (De Novo pathway) timeline in 4QCY26 (with the risk of some delay), then serving as a predicate for the First Responder to follow a couple years later via 510(k) clearance.

While this presents upside, the broker also noted given the stage of development, there are risks. 

We do not expect EMV to become cash flow positive until FY31, and as such it will continue to be reliant on grant and equity funding, which means it remains subject to both completing project milestones and capital markets.

Updated price target 

EMvision Medical Devices closed yesterday at $1.78 each. 

Bell Potter has placed a speculative "buy" recommendation and $2.95 price target on this healthcare stock. 

Based on this target, the stock price could be set to rise approximately 65%. 

Elsewhere, online brokerage platform Selfwealth has a similar view, listing the stock as undervalued by roughly 68%. 

The post This ASX healthcare stock could be a buy low bargain appeared first on The Motley Fool Australia.

Here's a run through of the results they posted to the market today.

Tesserent Ltd (ASX: TNT)

The Tesserent share price is leaping 8.7% to trade at 12.5 cents on Tuesday afternoon following the release of the company's financial year 2022 earnings. And what a financial year it was.

The cyber security service provider posted a $166 million turnover – representing a 71% year-on-year increase.

It also brought in $18.6 million of earnings before interest, tax, depreciation, and amortisation (EBITDA) on a normalised basis, representing a 94% lift.

Finally, its normalised net profit after tax (NPAT) rose 38% to $10 million.

EMvision Medical Devices Ltd (ASX: EMV)

Financial year 2022 was also good to EMvison Medical Devices, and the market apparently agrees. It's bidding the ASX medical imaging technology developer's stock 7.8% higher to $1.52 on the back of its earnings.

The company posted nearly $4.4 million of revenue for the financial year just been, 144% more than it did for the prior corresponding period (pcp).

Its losses also improved, lifting to a $6.1 million loss compared to financial year 2021's $8.4 million loss.

Energy Resources of Australia Limited (ASX: ERA)

Finally, the Energy Resources of Australia share price is lifting 2.8% to trade at 25.7 cents after the ASX-listed uranium producer dropped its half-year earnings today.

It posted an after-tax loss of $34 million for the six months ended June. That reflected lower sales volumes and higher non-cash costs. Its revenue from uranium sales also slumped 34% over the period to $35.3 million.

It comes after its Ranger Mine ceased operation in January 2021, meaning no uranium oxide was produced by the company last half. It also spent $80 million on rehabilitation activities at the Ranger Project Area over the half just been.

The post 3 ASX shares soaring on earnings updates appeared first on The Motley Fool Australia.

Shares in the Australian medical device company finished the session at $1.82, up 5.2%. Earlier, the EMvision share price reached an intraday high of $1.92 — up 10.98%.

By comparison, the All Ordinaries Index (ASX: XAO) also travelled higher today to 7,426 points — up 1.03%.

EMvision receives Modern Manufacturing Initiative Grant

ASX investors snapped up EMvision shares on news today that the company has been successful in its application for the grant.

According to a market release, the Department of Industry, Science, Energy and Resources has awarded EMvision a Modern Manufacturing Initiative (MMI) grant.

Under the MMI Manufacturing Translation Stream program, EMvision will receive $5 million of non-dilutive cash funding.

This program provides businesses with funds to support projects, adopt new technologies, and improve manufacturing processes. EMvision stated that the grant is a matched funding program and remains subject to agreeing documentation and terms.

EMvision has not provided any details on how the company will use the funds. Management said it will advise the details in due course.

The company is developing a portable brain scanner to diagnose and monitor strokes in patients.

The department will contact EMvision to discuss the next steps.

EMvision share price summary

Although the EMvision share price accelerated today, it has been on a downhill trend. The shares have lost 37% over the past 12 months and are down 31% year to date.

On valuation grounds, EMvision has a market capitalisation of roughly $133.95 million.

The post EMvision share price rockets 11% on $5 million pay day appeared first on The Motley Fool Australia.

Prior to their halt, EMVision shares closed at $1.94. Upon returning to trade, they have been sitting in the green amid the release of a company announcement. At the time of writing, EMvision shares are swapping hands at $2.05.

What did EMVision announce?

The company advised it has entered into an original equipment manufacturer (OEM) agreement with Keysight Technologies Inc (NYSE: KEYS).

According to the release, "Keysight is the world leader in radiofrequency (RF) test and measurement technology". Specifically, the company signed its agreement with Keysight's Australian subsidiary.

Under the agreement, EMvision will receive exclusive supply for 'fast sweep' features in the vector network analyser (VNA).

For reference, EMvision says the VNA is a custom solution developed in collaboration with Keysight.

"The VNA is a high performance, lower component count, miniaturised module responsible for accurate signal measurement," states the release.

"The custom VNA represents a strategic investment by Keysight into the electromagnetic imaging sector."

Regarding the announcement, EMvision CEO Dr Ron Weinberger says the collaboration "has been first class".

This Agreement recognises the roles that both parties have played in the development of the bespoke VNA over a period of 3 years. I would like to thank the Keysight team for their concerted work in developing a best-of-breed solution for EMvision and look forward to the commercial phase of our relationship.

Noteworthy is that Keysight is not a medical device manufacturer. However, it does possess "the strongest portfolio of Vector Network Analysers (VNA), which are core to the sensors that are being used inside EMvision's portable brain scanner," says the company.

The agreement builds on a relationship that spawned back in 2019. Then, the pair entered into a strategic collaboration to develop "custom healthcare-focused VNA solutions".

EMvision share price snapshot

In the last 12 months the EMvision share price has fallen more than 38%. Meanwhile, it is 23.5% in the red since trading resumed this year.

Following this announcement, shares have bounced from a low point and are tracking back towards monthly highs.

The post Here's why the EMvision share price surged 8% on Wednesday appeared first on The Motley Fool Australia.

EMvision's shares are on the move today after it announced an important update regarding a device application in the United States.

Here's what we know.

What did EMvision announce?

For context, EMvision is currently on the tools developing a portable medical imaging device that uses electromagnetic microwave imaging.

Its primary purpose is to diagnose the serious and complicated brain condition known as a stroke. However, it will diagnose other conditions as well.

EMvision advised it had received feedback from the US Food and Drug Administration (FDA) on its recent application for a Breakthrough Device Designation (BDD) in the US.

Under the Breakthrough Devices Program, applicants get priority review of their proposed therapy or intervention. This includes "interactive communication across the device development and validation path," per the release.

The release notes that preliminary evidence supports the use of its technology to "differentiate and localise" both types of stroke in patients.

However, the company reports that the FDA requires more clinical study data to support the case. It will need this before EMvision's device can get approval for the market.

As a result of the FDA feedback, EMvision advised it "has not been granted the BDD at this time."

It's not all over, though. The company still intends to go after the BDD once it has the clinical data on hand. EMvision will "generate [data] through further clinical development."

Importantly, the company emphasises that its pursuit of the "FDA De Novo regulatory marketing authorisation pathway" for its 1st Gen portable brain scanner product remains unaffected.

EMvision itself didn't appear to be fazed by the rejection. The medical tech company opting to take the feedback on board instead and get the ball rolling again.

Speaking on the announcement, EMvision CEO Dr Ron Weinberger said the company was "grateful for the quality feedback" provided by the FDA.

The decision has done little to deter the company's growth vision. Weinberger confirmed the marketing authorisation "remains unchanged, as does (its) preparation for expanded future clinical studies."

EMvision share price snapshot

The EMvision share price has had more than a choppy year so far, and has lagged the major benchmarks with a year-to-date loss of 5.81%.

Despite this, it's rallied 4% this past month, and is still 14% in the green over the past year.

Nonetheless, the EMvision share price has lagged the S&P/ASX 200 Index (ASX: XJO) gain of around 21% in the 12 months.

The post EMvision (ASX:EMV) share price slides 5% following FDA update appeared first on The Motley Fool Australia.

At the time of writing, shares in the medical device company are 14.07% higher to $3 apiece. However, earlier in trade the EMvision share price had been as high as $3.10.

Milestone achievement

Investors are excited about the potential for EMvision today after the company announced the latest development of its brain scanner. After working on prototyping and development of its portable medical technology, today EMvision has notched up an achievement.

According to the release, the company has successfully fabricated and assembled its alpha unit of its first-generation portable brain scanner. These units are intended for commercialisation, giving shareholders hopes for future sales.

However, before we get ahead of ourselves… the first-gen units will be the subjects of a range of tests for assessing compliance with regulatory standards. These include:

• Functional compliance,
• Reliability compliance,
• Integration (software and hardware) compliance,
• Safety compliance, and
• Performance compliance

In addition to the above-noted compliance tests, the units will also be assessed on suitability for manufacturing, assembly, shipment, environmental impact, use, service, and repair.

Furthermore, the intended use of portable brain scanners is in applications where conventional neuroimaging machines are not accessible or practical.

For example, co-chair of the Australian Stoke Alliance, Professor Stephen Davis AO mentioned the possibility of such technology being incorporated into standard ambulances and aircraft. This potential has fed into the excitement surrounding the EMvision share price.

Management commentary

Speaking on the monumental step, EMvision CEO Dr Ron Weinberger said:

This is an important milestone for the Company. Our product represents a game-changing opportunity to provide accessible point-of-care neuroimaging for stroke patients, wherever they are. The value proposition for our scanner is simple – portable, accessible, fast, safe, and affordable.

We are tackling the immense health burden that is stroke, with potential future adjacencies in traumatic brain injury and other neurological disorders. We see an enormous market opportunity ahead in neuroimaging that is poised for disruption. Our device will undergo various tests as we prepare for our next stage of expanded clinical studies.

EMvision share price recap

The EMvision share price has delivered an exceptional return to shareholders over the past year. This is despite bottom-line losses deepening as it continues to invest heavily in research and development. Specifically, over the course of the year, shares in the company have surged nearly 60%. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) has returned 23.4% during that time.

Finally, based on the current EMvision share price, the company holds a $216 million market capitalisation.

The post EMvision (ASX:EMV) share price leaps 14% on product update appeared first on The Motley Fool Australia.

By the market's close, the EMVision share price was trading at $3.16, up 4.29% from yesterday's closing price of $3.03.

Let's take a closer look at the latest news from EMVision.

What's driving the EMVision share price?

EMVision shares responded positively today after the company announced it has developed two new technologies. These will work alongside its prototype portable electromagnetic (EM) imaging device, currently being developed as a brain scanner.

The EM imaging device differs from other imaging technology currently available as it releases both electric and magnetic fields from its antenna which interact with brain tissue to produce an image. It has the potential to provide clinicians with diagnostic information in a non-invasive, radiation-free manner. 

EMVision states its two latest techniques have the potential to improve stroke diagnosis and care.

Once developed, the company hopes the two breakthroughs announced today can be accessed through its EM imaging device.

Dielectric mapping

The first of these breakthroughs is dielectric mapping. Dielectric mapping may be able to provide clinicians with anatomical detail to help them assess the impact of a stroke.

The company hopes dielectric mapping technology can be used as an alternative to MRI or CT imaging in the future. It states this could be particularly beneficial in situations when traditional imaging techniques are unable to be used, such as in ambulances or in a patient's home.

According to EMVision, its dielectric maps have been produced from data acquired by the company's prototype brain scanner.

Pulsatility

The second breakthrough announced by EMVision today is pulsatility. The company states pulsatility could potentially assist in the diagnosis of large vessel occlusion (LVO) for ischaemic strokes. LVO strokes are caused by a blockage to one of the major arteries in the brain. Early diagnosis and treatment of LVO strokes can have a significant impact on a patient's outcome. 

EMVision states that pulsatility technology could help reduce treatment delays and, therefore, the occurrence of resulting disability in patients. The technology could also minimise healthcare, insurer, and societal costs.

According to EMVision , since the technology has the potential to measure blood flow through the brain, it could help identify the degree of a blockage at its earliest stages. It could also help to localise any salvageable tissue and begin treatments to restore blood flow.

Expert commentary

Australian Stroke Alliance co-chair Professor Stephen Davis commented in the company's release, saying:

We hope that further advances in this technology will allow treatment of patients in rural and remote locations in Australia who would otherwise remain untreated.

Based on the very promising data from EMVision, we are engaged in preparing for multi-site clinical trials and it is hoped this will lead to future widespread application of this technology.

Management commentary

EMVision CEO Dr Ron Weinberger commented on the company's breakthroughs, stating:

The dielectric maps will have a dramatic impact on the interpretation of data from our algorithms. For the first time using EM imaging, clinicians will be able to make good approximations to the anatomical region at which stroke occurs and will enable a visualisation of the EM image for clinicians that is familiar to them and what they have been looking at for decades [using] CT and MRI…

 Pulsatility is a complimentary technique that alongside our existing diagnostic algorithms, has the potential to improve diagnosis and treatment and save more lives.

EMVision share price snapshot

Today's news comes at a good time for EMVision shares as they've had a lacklustre performance on the ASX so far this year.

Following today's boost, the EMVision share price is now up by 1.94% year to date. The company's shares are, however, up by 295% over the last 12 months.

EMVision has a market capitalisation of around $214 million, with approximately 70 million shares outstanding.

The post The EMvision (ASX:EMV) share price jumped today. Here's why appeared first on The Motley Fool Australia.

EMvision is focused on the commercialisation of a portable medical device for stroke diagnosis and monitoring as well as other medical imaging needs.

It's currently involved in the research and development of this medical imaging and diagnostic technology, which was previously licensed and subsequently acquired from Uniquest.

EMvision in the news this month

The only market update that EMvision has released this month was regarding the purchase of 17,200 shares at the value of $49,534 by company director Ronald Weinberger. 

That took place yesterday, but EMvision was also active in March through its presentation at the ASX Small and Mid-Cap Conference. The company presented plans for its portable brain scanner technology, which it's aiming to commercialise for use in future road/air ambulance models.

EMvision is currently in partnership with researchers at RMIT University and fellow Australian company Micro-X Ltd (ASX: MX1) to produce two prototype CT scanners, weighing 30kg to 100kg. A regular CT scanner weighs three tonnes. 

The post Why is the EMvision (ASX:EMV) share price surging 12% this week? appeared first on The Motley Fool Australia.

The EMvision share price finished off the trading session at $2.74 this afternoon.

Here's a wrap of where the funding will come from for the medical imaging technology provider, and why it may have moved the share price.

Australian Stroke Alliance wins bid

In today's release, EMvision advised that its commercial collaboration partner, the Australian Stroke Alliance (ASA), submitted a successful bid to the Stage 2 Medical Research Future Fund (MRFF) for a 5-year program to transform pre-hospital stroke care. 

The MRFF stage 2 program was awarded $100 million from the federal government, with 40 million allocated to ASA. 

Of the $40 million, ASA has advised EMVision that it will receive "$8 million of this non-dilutive cash funding in staged payments weighted to the earlier years of the program". 

This poses the opportunity for EMvision to commercialise its medical imaging technology and work toward further developments.

Executive commentary on funding

Commenting on the ASA collaboration, EMvision CEO Dr Ron Weinberger said:

The ASA brings together an end-to-end medical program to save and improve the lives of patients of one of the most debilitating medical emergencies in the world. No such consortium exists internationally, and the ASA will become a template for not only managing stroke, but other medical emergencies.

The ASA leadership has worked tirelessly to put Australia centre stage in this global battle to save healthy lives and is to be congratulated. We are grateful to the Australian government for recognising this vision and awarding one of the largest medical research grants in Australian history.

EMvision share price snapshot

Despite falling 22.4% year-to-date, the EMvision share price has gained 20.1% over the previous 6-month period.

The company's market capitalisation is approximately $171.2 million, and 70.8 million shares are outstanding.

The post Why the EMvision (ASX: EMV) share price closed 13% higher today appeared first on The Motley Fool Australia.

Let's take a look at why the small cap medical imaging company requested the pause in trading.

Why are EMVision shares paused?

The EMvision share price was brought to a standstill on Friday morning pending a further announcement by the company. EMvision has advised it is awaiting the outcome of a grant funding application and has requested its shares remain in the halt until the announcement is made or the commencement of normal trading tomorrow.

How has EMvision been performing?

Last Thursday, the EMvision share price was being pushed higher after the release of the company's half-yearly report for the period ending 30 December 2020.

EMvision reported strong revenue performance, delivering revenue of $1.67 million which was up 48% on the prior corresponding period (pcp). Nonetheless, this did not stop the company from posting a widening loss as it reported outflows of $3.21 million, up 78% on the pcp.

During the half, the company had grant income of $0.36 million, while it also received government support of $50,000. Operating expenses were principally made up of research and development costs associated with its technology.

Operating cash outflows for the half year were $1,059,119. However, thanks to the issuing of new shares financing, cash inflows came in at $8.7 million. As such, the company had a net asset position of $12.9 million as of 31 December 2020.

Commenting on the company's progress, management stated that:

As an early stage company, the company's business model is highly dependent on the achievement of continued technical development success as well as future funding, customer engagement and general financial and economic factors.

About the EMvision share price

It has been an average six months for the EMvision share price which has seen a rise of 7.56%. In comparison, the All Ordinaries Index (ASX: XAO) has returned 12.2% over the same period.

EMvision is an Australian company focused on the development and commercialisation of medical imaging technology. Primarily, it is focused on developing a cost-effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications.

Based on the current EMvision share price, the company has a market capitalisation of around $171 million.

The post Why the EMvision (ASX:EMV) share price is going nowhere appeared first on The Motley Fool Australia.

A week of good news for EMVision

EMVision's gains this week come after the company announced on Monday that it had received a $1.28 million cash refund for the financial year ending 30 June 2020. The incentive was paid to EMVision in relation to its research and development (R&D) work.

This brings EMVision's cash reserves to $13.1 million. Cash balance is of particular interest when looking at companies involved in R&D, where there are often gaps of time in between project developments.

On Thursday morning, EMVision announced the appointment of Professor Stuart Crozier as Chief Scientific Officer, noting that he is "globally recognised for his breakthroughs in Magnetic Resonance Imaging (MRI)".

Professor Crozier will now lead R&D efforts of EMVision's novel imaging products.

So what exactly does EMVision do?

Some Fools might recall us going into detail about what EMVision gets up to back in October. The company website states that EMVision "is developing a portable brain scanner for rapid, point of care, Stroke Diagnosis and Monitoring".

If that sounds complicated, it's probably because it is! Put simply, EMVision is working toward a solution that will support people suffering from a stroke, on-site. The company is currently developing a portable brain scanner that could save significant time diagnosing a stroke, therefore potentially lessening the impact of the stroke itself. 

According to a clinical trial result the company announced back in October, "It was observed that the EMVision device was able to classify stroke type (haemorrhagic or ischaemic) with an overall accuracy of between 93.3% and 96%."

More on the EMVision share price

EMVision shares have had an impressive 12 months. Year-over-year, the share price has rocketed over 300%. During its December 2018 IPO, EMVision's price was 25 cents a share. Lately, EMVision shares are trading in the $3 range, sitting at $3.16 at the time of writing.

With a market cap of around $213 million, EMVision certainly isn't the biggest player on the field, but it seems to be garnering plenty of attention since joining the game. 

The post Here's why the EMvision (ASX:EMV) share price is up 9% this week appeared first on The Motley Fool Australia.

Stroke causes an enormous health and economic burden throughout the world. It is the second leading cause of death and the third leading cause of disability globally. Imaging is the key to diagnosis and monitoring of acute stroke. 

In year-to-date trading, the EMvision share price has risen by 276% and has a current market capitalisation of $153 million. In addition, the company successfully completed a share placement for $6 million in July, underscoring investor interest in the technology. 

What did EMvision announce?

The results of EMvision's trial were resoundingly positive. First, the device was reportedly able to classify a stroke type (haemorrhagic or ischaemic) with an overall accuracy of between 93.3% and 96%. Second, it was able to localise targets in the correct brain quadrant with an overall accuracy of between 86.7% and 96%. 

The study enrolled and processed datasets from 30 patients with a diversity of stroke in localisation, size and severity. Moreover, the study has enabled the algorithm team to advance the hybrid 'fusion' methodology, a powerful approach to imaging. It works by extracting the target lesion and estimated location in each algorithm and applies a pixel-wise voting algorithm.

The fused image then leverages the classification algorithm. The algorithm team will continue to advance this fusion methodology in consultation with EMVision's clinical advisors. 

Why does this matter?

The rapid ability to classify stroke types and locations is valuable for time-sensitive treatment. Moreover, as noted by EMVision clinical advisor, Professor Michael O'Sullivan:

…Interesting future questions include the sensitivity of the technique for early detection of bleeding, both in the pre-hospital setting and in stroke units, where monitoring is currently limited to detection of clinical deterioration…

EMVision's CEO, Dr Ron Weinberger, commented:

These promising results, the first in stroke patients for our technology, provide a strong foundation with which to progress our development program. We are delighted by these results which indicate that we are able to discriminate and localize haemorrhagic and ischaemic strokes with an encouraging degree of accuracy under these conditions. We have exceeded our original objectives for this study. While we still have a way to go, we are well placed to develop our value proposition into a fully-fledged commercial product.

About the EMVision share price 

At the time of writing, the EMVision share price has fallen 3.17% lower to $2.75. The company's shares have recovered more than 500% from their March lows but are down nearly 13% from the 52%-week high of $3.15 reached earlier this month.

The post EMvision (ASX:EMV) share price falling despite positive results appeared first on The Motley Fool Australia.